{{Subject}}
Real Chemistry’s weekly analysis of biopharmaceutical pricing and value news, provided free of charge.
Real Chemistry
Value Report
November 6, 2026
 
 
Will Health and Drug Pricing Bills Ride the Blue Wave?

Even with about 25 federal races still uncalled as of publishing, Democrats have secured comfortable majorities in both chambers of Congress for the next two years.

Trends of “winners” and “losers” in the midterms became clear on election night. Several battleground seats were won by high-profile Democrats with a health or science background. Other candidates aligned with Make America Healthy Again suffered defeat, causing some to re-evaluate the future of HHS Secretary Kennedy’s movement.

After such decisive results, journalists and experts turned to projecting how that legislative power will translate into oversight and drug pricing actions. New leaders are expected to serve as a check on HHS’ controversial actions and pending nominees. Legislators are expected to whip up support for bipartisan 340B reforms and expansions of federal drug price controls.

On the other hand, some analysts believe Democrats have “bigger fish to fry” than drug pricing—and the split between Congress and the White House naturally limits the scale of possible reforms. Biopharma leaders appear unfazed as well, looking forward to minting new industry champions after unprecedented turnover on Capitol Hill.

Tenured Democrats have already begun jockeying for leadership positions on healthcare committees. Sen. Ron Wyden, D-Ore., has previewed an agenda of accountability and stopping the “corporate chokehold” on U.S. healthcare, while Sen. Bernie Sanders, I-Vt., will balance advocacy for ambitious ideas with a high-stakes negotiation on FDA user fees.

All in all, there’s a ton to unpack. We’ll have more to say on midterms on Real Chemistry’s blog early next week.

– Andrew Wishon, Editor-in-Chief

CVS Breaks Up Its Healthcare Empire

CVS Health announced plans to split itself into two public companies, unwinding the $69 billion Aetna acquisition. One entity will include Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, CVS Pharmacy, will include roughly 9,000 stores, mail pharmacy, MinuteClinic and the Health100 technology business. The separation is expected to be completed in the first half of 2028.

CVS is framing the move as a strategic one, giving each business sharper focus, independent capital structures and “greater agility” to respond to “regulatory and other external dynamics.” CEO David Joyner asserted that regulation was not the reason for the split, calling it instead the next step in CVS’s “evolution.” Drug Channels’ Adam Fein views it similarly, arguing that regulatory risks are ”real” but secondary to whether the synergies between retail pharmacies and Caremark actually materialized. On the other hand, media coverage has called the move a “stunning reversal of strategy” and “indictment” of vertical integration.

Despite CVS’ messaging, it is hard to separate CVS’s decision from the regulatory environment around it. Tennessee and Arkansas have enacted laws barring common ownership of pharmacies and PBMs. CVS says those laws would force it to close 134 pharmacies in Tennessee and 23 in Arkansas, and it is challenging both in court.

The push has also become increasingly bipartisan, especially through the Hawley-Warren Patients Before Monopolies Act. The Democrats’ midterm wins mean scrutiny is expected to continue in 2027.

– Megan Hickey, Managing Director

Circled on Our Calendar
Quotes of the Week
  • “As election night fades, the possibility of a new alliance is coming into view: Democrats, a party with a long history regulating industry and MAHA (maybe they’ll take a new name?), a grassroots movement with energy and organization” – Brinda Adhikari and Tom W. Johnson, STAT
  • “Congress, the administration, and the broader healthcare community should recognize that the [FDA] commissioner’s most consequential decisions often concern matters that never make headlines” – Peter Reikes, BioCentury
  • “The story this year is not about out-of-control employer health costs—they were moderate—or of a collapsing employer-based insurance system, although it certainly has many problems…Instead, the story this year seems to be a conspicuous shift of premium costs to workers despite a moderate overall premium increase” – Drew Altman, KFF
Other News
See you next week …
–  Real Chemistry
 
Know a friend or colleague that would enjoy the Value Report?
Invite them to sign up here.
© Real Chemistry, All Rights Reserved.